Sage Group Announces OncoSec Collaboration For TAVO™ Gene Therapy In Australia With Emerge Health

top of page

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

Featured Posts

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Recent Posts

Sage Advises Hatchtech on Pelthos Therapeutics Acquisition of Xeglyze® (abametapir) Topical Treatment for Head Lice

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Serpin Pharma Partners with Dogwood Therapeutics to Develop and Commercialize SP16 as a Treatment for Cancer-Related Pain

Sage Group Advises Fabre-Kramer Pharma on Partnering Deal with Aytu Biopharma for EXXUA(TM), a Newly Approved and Innovative Treatment for Major Depressive Disorder

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)

Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors

Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells

Archive

Search By Tags

Follow Us

bottom of page